IVI opens Country Office in Austria

Logo PR Newswire
PR Newswire

SEOUL, South Korea, Jan. 25, 2023 /PRNewswire/ -- The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, announced today the launch of an IVI Country Office in Austria. This new office signals a step forward for Austria's ambition to dial up efforts in vaccine research and development, and IVI's initiative to work closely with the Austrian government and local research network and biomedical industry.

Dr. Jerome Kim, Director General of IVI, said, "We are thrilled to share that IVI has launched its Austria Country Office in the country's capital, well established in areas of international cooperation and eager to advance its growing R&D ecosystem. In addition to IVI's Europe Regional Office in Stockholm, these two sites will generate joint grant proposals with local partners and mobilize collaborative vaccine R&D projects for global health. We are deeply thankful to the Federal Ministry for European and International Affairs of Austria for supporting the opening of this office."

The Foreign Minister of Austria, Alexander Schallenberg, said, "Austria continues to live up to its reputation as a place of encounter and international dialogue, now also increasingly in the field of vaccine research. The Vienna office will be strengthened by the location of the IVI branch and the contribution of international organizations to value creation in Austria will be increased."

On December 14, 2022, Director General Kim and H.E. Wolfgang Angerholzer, Ambassador of Austria to the Republic of Korea, signed a Seat Agreement at IVI headquarters in Seoul, Republic of Korea, securing IVI's status as an international organization hosted by the Government of Austria.

IVI is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme. 39 countries and the WHO are signatories to IVI's founding treaty, and Austria's application for membership is currently in progress. According to the Federal Ministry for European and International Affairs (BMEIA) of Austria, the government will invest an annual amount of 860,000 euros in IVI, a contribution to Austria's vaccine development in Europe and globally.

The governments of the Republic of Korea, Sweden, India, and Finland currently provide state funding, and Denmark made a core contribution of 4 million Danish kroner in 2022.

Cision View original content:https://www.prnewswire.co.uk/news-releases/ivi-opens-country-office-in-austria-301730047.html

Logo EIN Presswire
HealthPress Release2023-01-24 12:04:42
Diabetes Vaccine Market Diabetes is one of most prevalent chronic diseases worldwide. BURLINGAME, CA, UNITED STATES, January 24, 2023 / EINPresswire.com / --...

Logo EIN Presswire
HealthPress Release2023-01-24 19:26:25
Omega Bio-tek IVDR products Omega Bio-tek shares the European Commission's commitment to the highest quality standards. We remain committed to providing...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:30:00
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Dyadic, we, us, our, or the Company) (NASDAQ: DYAI), a global biotechnology...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:30:00
Press Release Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023 January 24, 2023 release at 7:30 am CET Sophia...

Logo PR Newswire
HealthPress Release2023-01-24 20:27:00
CHICAGO, Jan. 24, 2023 /PRNewswire/ -- Unity MSK, a management services company providing support to orthopedic and podiatric practices across the United...

Logo Global News
HealthBy Jeanelle Mandes2023-01-23 23:30:13
The Regina Open Door Society (RODS) runs a program that provides resources for newcomers and refugees such as COVID-19 vaccinations. Transitioning to a new...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-23 12:45:00
Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts KBI Biopharma, Inc. (KBI), a...

Logo The Guardian
HealthBy Henry Belot2023-01-25 00:00:05
Australias national vaccine advisory body is expected to decide within weeks if a fifth Covid vaccine dose will be made available to more Australians this...

Logo PR Newswire
HealthPress Release2023-01-25 02:45:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The Human Combination Vaccines Market by Type, Channel, and Geography - Forecast and Analysis 2023-2027 report has...

Logo PR Newswire
SAN JOSE, Calif., Jan. 24, 2023 /PRNewswire/ -- Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. ("MGI"),...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...

Logo EIN Presswire
With a Network of Over 75,000 Remote Brand Ambassadors, Omni Interactions Continues to Deliver Exceptional Customer Experience For one client last year, we...

Logo PR Newswire
PLANO, Texas, Jan. 24, 2023 /PRNewswire/ -- Hilti Group commits to the Science Based Targets initiative (SBTi) in line with the goals of the Paris Agreement....

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, January 24, 2023 / EINPresswire.com / -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and...

Logo GlobeNewswire
TechnologyPress Release2023-01-24 23:00:00
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 13:06:59
23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million Clinigen Limited (Clinigen') (the Company'), the global...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 11:17:00
Immunis Inc. is a private biotechnology company recruiting participants between the ages of 50-75 with muscle atrophy related to knee osteoarthritis for its...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...